• Best Practices New Normal
  • Digital Dentistry
  • Data Security
  • Implants
  • Catapult Education
  • COVID-19
  • Digital Imaging
  • Laser Dentistry
  • Restorative Dentistry
  • Cosmetic Dentistry
  • Periodontics
  • Oral Care
  • Evaluating Dental Materials
  • Cement and Adhesives
  • Equipment & Supplies
  • Ergonomics
  • Products
  • Dentures
  • Infection Control
  • Orthodontics
  • Technology
  • Techniques
  • Materials
  • Emerging Research
  • Pediatric Dentistry
  • Endodontics
  • Oral-Systemic Health

Telemedicine To Help Vivos Therapeutics Expand Into Orofacial Myofunctional Therapy


Vivos to offer MyoCorrect via telemedicine for all Vivos-trained clinicians to use as therapeutic protocol in tandem with the Vivos System.

Vivos' MyoCorrect

Vivos Therapeutics, Inc., is taking yet another step in becoming an impact player in the growing need to help people suffering from sleep disorders.

The medical technology company, focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), just announced that it will launch a new service called MyoCorrect, where trained therapists will provide Vivos-trained providers access to orofacial myofunctional therapy (OMT) via telemedicine technology as a component to OSA treatment using the Company’s Vivos System.

Related Reading: A New Approach to Sleep-Disordered Breathing

Vivos expects to see additional revenue from its new MyoCorrect service in the form of increased Vivos System cases and fees charged for the service. The company believes the MyoCorrect service will become an important value-added component in the treatment of OSA using the Vivos System. Further the company believes that offering OMT as a service will provide it with an additional competitive advantage in the OSA treatment marketplace.

OMT therapists work to strengthen and improve function in the muscles of the lips, tongue, cheeks and face and their related roles in breathing, sucking, chewing, swallowing, and some aspects of speech. Research has shown OMT to be an effective component of OSA treatment. Vivos plans to make the MyoCorrect protocol available as a component of their system and will actively integrate training and implementation protocols for Vivos-trained dentists to utilize the MyoCorrect therapy.

According to the company, Vivos-trained dentists who have actively incorporated OMT into their Vivos System treatment protocols report 4 primary benefits: (1) higher case acceptance, (2) better patient compliance, (3) shorter treatment times, and (4) improved clinical outcomes. However, due to scarcity of trained OMT therapists in many areas and other factors, too few dentists and patients have been able to access this important adjunctive therapy. MyoCorrect will provide every Vivos dentist with immediate and easy access via telemedicine to this valuable clinical resource at an attractive price point.

“We believe this clinical enhancement to our flagship Vivos System treatment for mild-to-moderate OSA will work synergistically within the emerging Vivos dental sleep medicine ecosystem. This ecosystem features extensive clinical training through the Institute for Craniofacial Sleep Medicine, Vivos AireO2 practice management software, Vivos Airway Intelligence Services, Vivos Billing Intelligence Services, VivoScore diagnostic devices powered by SleepImage, our proprietary Vivos System oral appliance therapy, and multidisciplinary collaboration between physicians and Vivos dentists through the growing network of Vivos-trained dentist offices and Pneusomnia clinics,” Vivos’ Chairman and CEO Kirk Huntsman says.

The launch of MyoCorrect follows the acquisition by Vivos of certain assets from and the entry into related agreements with MyoCorrect, LLC and its affiliates. MyoCorrect, LLC is a healthcare provider based in New York that specializes in the delivery of OMT via telemedicine.

Related Videos
2024 Dental Products Report Spring Selection Bracket Reveal Video
Addressing Unmet Needs in Early Childhood Oral Care - an interview with Ashlet Lerman, DDS
2024 Chicago Dental Society Midwinter Meeting – Interview with Peter Maroon, business development and sales lead at Spectrum Solutions® on the new salivary diagnostic test, SimplyPERIO.
Product Bites – March 8, 2024 Part 2
Product Bites – March 8, 2024 Part 1
Contemporary Cosmetic Dentistry – Part II: Arresting Marginal Caries
GNYDM23 Product Focus: CandidPro with Kristin Lange, VP of Sales at Candid
Greater New York Dental Meeting 2023 – Interview with Suzanne Cano from LunaLite Dental
Greater New York Dental Meeting 2023 — Interview with Shannon Carroll, RDH
© 2024 MJH Life Sciences

All rights reserved.